Preclinical News and Research

RSS

Sanofi-aventis acquires world-wide license for ADC products

Oxford BioTherapeutics today announces that sanofi-aventis has acquired an exclusive world-wide license to one of OBT's internal preclinical antibody programs.

25 Jan 2011

New study on pain-relieving effect of transcutaneous Vagus Nerve Stimulation

The medical device company cerbomed cooperated with the Clinic for Psychiatry and Psychotherapy of the University of Regensburg 2010 on a randomized, controlled study into somatosensory pain processing. The study, lead by Prof. Dr. Peter Eichhammer and Dr. Volker Busch, aimed to judge the pain-relieving effect of transcutaneous Vagus Nerve Stimulation (t-VNS).

25 Jan 2011

RRD enters partnership with NIH Therapeutics for Rare and Neglected Diseases program

RRD International, a strategy-driven biotech and pharmaceutical product development company, announced today that it has entered into a partnership with the National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program as a regulatory support and development partner.

25 Jan 2011

SNM commends FDA Advisory Committee recommendation for florbetapir approval

The Society of Nuclear Medicine (SNM) commends the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee on its recent recommendation for conditional approval of a new imaging agent, florbetapir.

25 Jan 2011

Fat grafting safety review published; no increased risk of cancer

Published clinical experience in over 2,000 patients who received autologous fat grafts showed no evidence of increased risk of development, metastasis or recurrence of breast cancer in contrast to laboratory data.

24 Jan 2011

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Agenus Inc. today announced it has entered into a research agreement with Memorial Sloan-Kettering Cancer Center (MSKCC) using Agenus' proprietary cancer vaccine technology.

24 Jan 2011

KineMed's fibrosis research program featured in Nature Medicine

KineMed Inc.'s fibrosis research program, which aims to advance the discovery and development of drugs to treat this major disease, is featured in the January edition of Nature Medicine.

24 Jan 2011

Sunshine and Binghamton University enter research agreement for cancer compound

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).

21 Jan 2011

MedImmune announces MEDI-573 preclinical results against many solid tumors

MedImmune's Oncology group announced today preclinical results showing that MEDI-573, a targeted monoclonal antibody, broadly suppresses pathways that have been shown to play a critical role in the development and progression of many solid tumors.

21 Jan 2011

Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, announced that Teva Pharmaceutical Industries Limited (Teva) purchased 2,334,515 shares of Rexahn's common stock in a private offering for $3.95 million, or $1.692 per share.

21 Jan 2011

Researchers discover nitroxoline can reduce human breast, bladder cancer cell growth

Researchers at the Johns Hopkins University School of Medicine have discovered that nitroxoline, an antibiotic commonly used around the world to treat urinary tract infections, can slow or stop the growth of human breast and bladder cancer cells by blocking the formation of new blood vessels.

20 Jan 2011

Cognition Therapeutics closes $2.5 million Series A1 financing

Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer's, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status. The round was led by Golden Seeds, one of the nation's largest angel investing groups, and was syndicated with Tech Coast Angels.

20 Jan 2011

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma Grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

20 Jan 2011

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.

20 Jan 2011

Study validates MultiStem as potential stem cell therapy for spinal cord injury

Case Western Reserve University School of Medicine and Athersys, Inc. announced a joint scientific study on spinal cord injury will be published today in the January issue of The Journal of Neuroscience.

20 Jan 2011

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

4SC AG, a drug discovery and development company, today announced that the first patient has been dosed in the Phase I/II SHORE study with the oral pan-histone deacetylase (HDAC) inhibitor resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.

20 Jan 2011

Theraclone, Pfizer enter multi-year research and development collaboration

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that they have entered into a multi-year research and development collaboration with Pfizer. The collaboration will use Theraclone's I-STAR™ technology to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.

19 Jan 2011

Case Western Reserve, Athersys enter partnership for scientific study on spinal cord injury

19 Jan 2011

Positive preliminary results from Soligenix's SGX202 in GARS model

Soligenix, Inc., a late-stage biopharmaceutical company, announced today promising preliminary results from a preclinical study of SGX202 in a canine gastrointestinal acute radiation syndrome model.

19 Jan 2011

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

Following a successful Phase 1 study for safety, researchers at MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 2 clinical trial testing the ability of a human monoclonal antibody they developed to prevent hepatitis C virus infection of a donor liver in transplant patients.

19 Jan 2011

Preclinical News and Research

Sanofi-aventis acquires world-wide license for ADC products

New study on pain-relieving effect of transcutaneous Vagus Nerve Stimulation

RRD enters partnership with NIH Therapeutics for Rare and Neglected Diseases program

SNM commends FDA Advisory Committee recommendation for florbetapir approval

Fat grafting safety review published; no increased risk of cancer

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

KineMed's fibrosis research program featured in Nature Medicine

Sunshine and Binghamton University enter research agreement for cancer compound

MedImmune announces MEDI-573 preclinical results against many solid tumors

Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117

Researchers discover nitroxoline can reduce human breast, bladder cancer cell growth

Cognition Therapeutics closes $2.5 million Series A1 financing

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Study validates MultiStem as potential stem cell therapy for spinal cord injury

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

Theraclone, Pfizer enter multi-year research and development collaboration

Case Western Reserve, Athersys enter partnership for scientific study on spinal cord injury

Positive preliminary results from Soligenix's SGX202 in GARS model

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News